Latest news
Intellia Prepares for Anticipated 2027 Commercial Launch of First In Vivo Gene Editor - precisionmedicineonline.comprecisionmedicineonline.com · Thu, 06 Aug 2026 19:23:40 GMTIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia TherapeuticsIntellia Therapeutics · Thu, 06 Aug 2026 11:05:12 GMTScientists discover in vivo gene transfer behind extreme antibiotic resistance - Drug Discovery NewsDrug Discovery News · Wed, 05 Aug 2026 13:56:03 GMTCRISPR Therapeutics Launches Clinical Trials of In Vivo Gene Editors for Hypertension, AATD - precisionmedicineonline.comprecisionmedicineonline.com · Tue, 04 Aug 2026 14:29:21 GMTAEGIS Targets Personalised Editing for Childhood Immune Disorders - CRISPR Medicine NewsCRISPR Medicine News · Fri, 31 Jul 2026 10:13:42 GMTIn vivo base editing presents promising therapeutic direction for Huntington’s - BioTechniquesBioTechniques · Fri, 31 Jul 2026 07:00:00 GMTJ&J pays Sail $785M, charting course to possible in vivo CAR-T buyout - Fierce BiotechFierce Biotech · Thu, 30 Jul 2026 07:00:00 GMT